AI TechnologyAbsci's AI-driven platform can design antibodies to precisely target an epitope with optimized interface contacts to ensure high potency and affinity, setting itself apart from competitors.
Clinical AdvancementAbsci has dosed the first participant in ABS-101's Ph1 trial, marking its transition into a clinical stage biotech.
Partnership OpportunitiesManagement cited strong potential partnership interest for ABS-101, allowing for a collaboration independent of the TL1A bispecific that Absci is progressing through its early pipeline.